Skip to main content

Security report for bbbiotech.ch

BB Biotech AG · Healthcare · Switzerland

Medium risk. 8 critical or high findings in Security headers, GDPR outside view and 1 other check.

Security score

51/100

Risk levelMedium

0–100, higher is better. How it is calculated

BB Biotech AG is a leading investment company specializing in the biotechnology sector, with over 30 years of experience and a strong market presence on the SIX Swiss Exchange and Frankfurt Stock Exchange. The company focuses on investing in listed biotech companies developing innovative drugs addressing unmet medical needs. The website reflects a mature digital infrastructure built on the Neos CMS and Flow PHP framework, employing modern JavaScript libraries and analytics tools to deliver a responsive and user-friendly experience. Security posture is solid with HTTPS enforcement and cookie consent mechanisms, though there is room for improvement in publishing explicit security policies and incident response contacts. Overall, the site demonstrates high professionalism, transparency, and compliance with privacy regulations, supporting BB Biotech's credibility as a trustworthy investment entity.

Scanned

NIS2 and GDPR posture

GDPR outside view
35/ 100 · High
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

8 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Strict-Transport-Security header

      Forces HTTPS connections

      What to do: Add "Strict-Transport-Security: max-age=31536000; includeSubDomains; preload"

      • CWE-319
      • OWASP A04:2025
      • ASVS V3.4.1
    • High

      Missing X-Frame-Options header

      Prevents clickjacking attacks

      What to do: Add "X-Frame-Options: DENY" or "X-Frame-Options: SAMEORIGIN"

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Privacy Policy found

      GDPR requires a clear and accessible privacy policy

      What to do: Add a comprehensive privacy policy page and link to it prominently

    • High

      No Cookie Policy found

      GDPR requires clear information about cookie usage

      What to do: Add a dedicated cookie policy explaining cookie usage and purposes

Need hands-on remediation? Email guard@offseq.com

Keep watching bbbiotech.ch

This scan found 24 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
47
Security headers
15
Email security
83
DNS health
85
Network security
40
GDPR outside view
35
Average
51

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

BB Biotech AG operates in the healthcare investment sector, targeting fast-growing biotechnology companies with promising drug pipelines. Its business model revolves around portfolio management and investment in publicly listed companies, leveraging its expertise and market knowledge. The company maintains strong investor relations, transparent financial reporting, and ESG commitments, including inclusion in the SPI ESG Index. The website's partnership with Bellevue Asset Management AG and integration of financial data services enhance its operational ecosystem. The target audience includes individual investors and investment professionals seeking exposure to biotech investments. The company's market position is robust, supported by consistent branding and comprehensive content.

Security posture

The website exhibits a good security posture with mandatory HTTPS, cookie consent, and disclaimers addressing legal and data protection aspects. However, explicit security headers such as Content-Security-Policy and X-Frame-Options are not clearly present, and no dedicated security policy or incident response contact is published. There is no evidence of exposed sensitive data or vulnerable libraries. The absence of a vulnerability disclosure policy or security.txt file suggests an opportunity to enhance transparency and readiness. Overall, the security maturity is moderate to high, suitable for a financial investment website but with room for further hardening.

Recommendations

  1. Implement and verify comprehensive security headers including CSP, X-Frame-Options, and X-Content-Type-Options.
  2. Publish a dedicated security policy page and provide incident response contact information.
  3. Establish a vulnerability disclosure program or security.txt file to encourage responsible reporting.
  4. Regularly audit third-party scripts and analytics tools for security and privacy compliance.
  5. Enhance transparency around data retention policies and user privacy practices.

Contact details published on the site

Addresses
Legal name
BB Biotech AG
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
BB Biotech AG
Description
BB Biotech AG invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with more than 30 years of experience. Its investments focus on listed companies developing and commercializing novel drugs that offer sound value for the healthcare system.
Key services
Investment management, Portfolio management, Financial reporting, Investor relations
Content quality
excellent
Branding
consistent

Technology

Stack
PHP, JavaScript, Alpine.js, UIkit, Google Tag Manager, Jentis Analytics, LazySizes (lazy loading images), Iframe Resizer
Frameworks
Neos CMS, Flow PHP framework
Performance
moderate
Mobile
good
Accessibility
good
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent mechanism implemented
  • Disclaimer and legal notices present
  • No exposed sensitive data in HTML
  • Use of secure forms with consent

Analytics and tracking

Services
Google Tag Manager, Jentis Analytics
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Jentis Analytics
Marketing tools
Jentis Analytics
Transparency
good

Site quality

Design
excellent
User experience
excellent
Content relevance
excellent
Navigation
excellent
Professionalism
excellent
Trustworthiness
high

Key observations

  1. Website is professionally designed and well-structured.
  2. Strong focus on investor relations and transparency.
  3. Comprehensive legal disclaimers and cookie consent mechanisms.
  4. Use of modern web technologies and CMS (Neos).
  5. No signs of malicious or suspicious activity.
  6. Social media presence on LinkedIn and Twitter supports legitimacy.
  7. No security policy or incident response contact publicly available.
  8. No vulnerability disclosure or security.txt found.
Technical notes

Notes

The website is built on the Neos CMS platform using the Flow PHP framework, leveraging modern JavaScript libraries such as Alpine.js and UIkit for UI components. It integrates Google Tag Manager and Jentis Analytics for tracking and marketing purposes. Lazy loading of images is implemented via LazySizes, improving performance. The site is mobile-optimized with responsive design and accessibility considerations. Performance is moderate, with potential for optimization in script loading and asset management. Hosting provider details are not explicit, but the infrastructure supports secure HTTPS connections. Overall, the technical stack is modern and well-maintained, supporting the business goals effectively.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with bbbiotech.ch. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review bbbiotech.ch.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.